本帖最后由 老马 于 2013-3-13 13:43 编辑 # ^- ^: w& i& n V& t
' T$ K: g7 p" K/ ]健择（吉西他滨）+顺铂+阿瓦斯汀6 X+ n( a6 k& n/ a* f
Gemzar +Cisplatin + Avastin
# N9 S% o7 D& W+ L# ?http://annonc.oxfordjournals.org/content/21/9/1804.full
5 C$ ~( k- r3 t" XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 D+ p( A2 W- [. c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% k# F' {7 V: U* w% sResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. E8 M6 D2 z: S! G
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 252)
( H/ i$ y j$ O) c7 f华为网盘附件：
( e$ k j7 d/ l2 ?5 v/ O; r) G( G【华为网盘】ava.JPG
1 h8 Y: H3 t0 |9 @6 }7 \ |
显身卡
